Great Novel Therapeutics Biotech & Medicals (TPEX:7427)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
32.50
+0.85 (2.69%)
Mar 10, 2026, 1:59 PM CST
-23.98%
Market Cap 1.36B
Revenue (ttm) 1.78M
Net Income (ttm) -87.75M
Shares Out 42.95M
EPS (ttm) -2.03
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 59,969
Average Volume 269,025
Open 31.85
Previous Close 31.65
Day's Range 31.85 - 32.60
52-Week Range 29.50 - 57.00
Beta -0.05
RSI 39.30
Earnings Date Mar 27, 2026

About TPEX:7427

Great Novel Therapeutics Biotech & Medicals engages in the development of drugs for the treatment of advanced and refractory cancers. The company develops drugs for cancer immunotherapy, including tumor microenvironment regulators, epigenetic immunoactivators, and immune-regulating multi-kinase inhibitors. The company was formerly known as GNT Biotech & Medicals Corporation. Great Novel Therapeutics Biotech & Medicals was founded in 2013 and is based in Taipei, Taiwan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Employees 15
Stock Exchange Taipei Exchange
Ticker Symbol 7427
Full Company Profile

Financial Performance

In 2024, TPEX:7427's revenue was 1.69 million, a decrease of -65.26% compared to the previous year's 4.85 million. Losses were -104.92 million, 72.0% more than in 2023.

Financial Statements

News

There is no news available yet.